Although the trial did not see a benefit in Based Composite Lupus Assessment (BICLA), the drug did provoke anti-IFN-α2b serum antibodies and decreased the IFN gene signature in 91% of patients. The gene discussed is IFNA2; the disease is systemic lupus erythematosus.